Practical Guidance for Prostate Cancer Imaging: PSMA-PET Scans and Patient Selection

David Albala, MD, shares closing advice on using PSMA-PET scans in prostate cancer management and making informed patient selection decisions based on guidelines and practical insights.

EP: 1.An Overview of PSMA-PET Scans and Prostate Cancer Imaging

EP: 2.Advancements in Prostate Cancer Imaging: The Evolution of PET Scans

EP: 3.Prostate Cancer Imaging: PSMA Agents and Radiotracer Options

EP: 4.Challenges and Progress in Advanced Imaging for Prostate Cancer

EP: 5.CMS Reimbursement Shift in Prostate Cancer: Streamlining Radiotracer Payments

EP: 6.Prostate Cancer Imaging and Care in 2023: Best Practices

Now Viewing

EP: 7.Practical Guidance for Prostate Cancer Imaging: PSMA-PET Scans and Patient Selection

Related Videos

Related Content

Advertisement

February 3rd 2025

Acute toxicity after prostate cancer radiotherapy increases odds of late toxicity

Hannah Clarke

The incidence of late grade 2 or greater GU toxicity at 5 years was 12.5% among those who did experience acute toxicity vs 7.5% among those who did not.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 28th 2025

Trial of immune therapy in mCRPC expands enrollment to VA medical center

Hannah Clarke

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 27th 2025

Testosterone therapy and prostate cancer: Risk-benefit and individualized treatment

Mohit Khera, MD, MBA, MPH

“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH.

January 23rd 2025

Standard pathology reports may be difficult to understand for patients with prostate cancer

Hannah Clarke

Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.

Related Content

Advertisement

February 3rd 2025

Acute toxicity after prostate cancer radiotherapy increases odds of late toxicity

Hannah Clarke

The incidence of late grade 2 or greater GU toxicity at 5 years was 12.5% among those who did experience acute toxicity vs 7.5% among those who did not.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 28th 2025

Trial of immune therapy in mCRPC expands enrollment to VA medical center

Hannah Clarke

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 27th 2025

Testosterone therapy and prostate cancer: Risk-benefit and individualized treatment

Mohit Khera, MD, MBA, MPH

“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH.

January 23rd 2025

Standard pathology reports may be difficult to understand for patients with prostate cancer

Hannah Clarke

Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.